When I first heard about Parsley Health close to a decade ago, the startup embodied a few trends I was following closely: primary care startups and cash-pay healthcare. For a …

A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland-based biotech called …

BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of companies moving production to the US becomes clear. According to …

Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company reported in

Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor’s poop. A biotech startup has studied the woman’s stool and …

Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy’s failure in two mid-stage trials. The company said that JNJ-4804, a combination of the blockbuster drugs Tremfya …

Cytokinetics’ Myqorzo has succeeded where BMS’s first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.

Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field’s broadest …

Big healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find that creating tools internally …

Researchers have used a machine learning algorithm to try to work out why Parkinson’s disease patients can respond so differently to treatment.